İmatinibin Sıçan Karaciğerine Etkisi

KUYUCU Y., SENCAR L.

Med Bull Haseki, vol.59, no.1, pp.58-62, 2021 (TRDizin) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.4274/haseki.galenos.2021.6667
  • Journal Name: Med Bull Haseki
  • Journal Indexes: TR DİZİN (ULAKBİM)
  • Page Numbers: pp.58-62
  • Keywords: Imatinib, liver, ultrastructure, MESYLATE THERAPY, KINASE INHIBITOR, GROWTH-FACTOR, EXPERIENCE
  • Çukurova University Affiliated: Yes

Abstract

Aim: Imatinib is a protein tyrosine kinase inhibitor that's used as an anticancer drug. In this study, evaluation the effects of different doses of imatinib on liver ultrastructurally and biochemically was aimed.